Ankylosing Spondylitis Clinical Trial
Official title:
Clinical Trial of Osteoporosis in Ankylosing Spondylitis
This is an observational study aiming to study the prevalence and risk factors for osteoporosis and vertebral fractures in patients with ankylosing spondylitis attending three Rheumatology clinics in Western Sweden.
Background Ankylosing spondylitis (AS) is a common inflammatory rheumatic disease with a
prevalence of 0.5-1.0%. Men are more commonly affected by the disease as compared to women,
ratio 2.6-4:1. Pain in the back is a frequent symptom of debut. This pain is often
associated with sacroilitis. In later stages also the lumbar, thoracic and cervical spine
are hit by the disease. Peripheral joints, eyes, heart, lungs and urinary tract may also be
influenced.
Osteoporosis in AS In AS the risk of osteoporosis is increased. However, this field has not
yet been significantly studied probably due to several reasons such as the predominance of
men with the disease and men are more seldom investigated for osteoporosis compared to
women. When AS progresses syndesmophytes of the spine are developed which makes it difficult
to assess bone mineral density (BMD) correctly with the conventional method, dual energy
x-ray absorptiometry (DXA). Fractures in the spine are easy to foreseen since the pain of
the patient might be misjudged to be related to increased disease activity. Fractures are
also overlooked in radiographs in AS. AS is associated with both increased bone formation
and increased bone resorption. The bone remodeling process in the spine renders the spine
less flexible and stiffer and as a consequence also a quite small trauma may result in a
fracture. These fractures are often instable risking injuring the spinal cord and nerves.
Aims of the study
- To investigate the prevalence of osteoporosis and osteoporosis related fractures in
patients with AS in Western Sweden.
- To identify risk factors for osteoporosis and osteoporosis related fractures in AS.
- To study how fractures in the spine may influence the pain in the back, the flexibility
of the spine and the posture of the patients.
- To study to which extent the patients with AS are investigated and treated for
osteoporosis.
- To investigate which method is most reliable for measuring BMD in AS.
Design and methods This is an observational study consisting of questionnaires, examination
of the patients, blood tests, measures of BMD with different techniques, DXA, both
frontal-dorsal and lateral projections, Quantitative Computed Tomography (QCT) and Xtreme
CT. Patients with AS from three rheumatology clinics in western Sweden with definite AS will
be invited to participate. It is estimated that about 250 patients will be included in the
trial. All patients gave informed written consent according to the Declaration of Helsinki.
The study has been approved by the Regional Ethics Committee.
;
Observational Model: Case-Crossover, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02685904 -
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
|
Phase 3 | |
| Completed |
NCT02186873 -
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
| Completed |
NCT01668004 -
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
|
Phase 4 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Completed |
NCT01934933 -
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
|
Phase 4 | |
| Not yet recruiting |
NCT04875299 -
Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
|
||
| Completed |
NCT02763111 -
Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis
|
Phase 2 | |
| Completed |
NCT02758782 -
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis
|
Phase 4 | |
| Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
| Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
| Completed |
NCT01750528 -
Prevalence and Progression of Periodontitis in Ankylosing Spondylitis
|
N/A | |
| Completed |
NCT01463189 -
Web-based Support to Manage Arthritis Pain
|
Phase 2 | |
| Completed |
NCT01091675 -
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
|
Phase 3 | |
| Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
| Recruiting |
NCT00747578 -
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
|
N/A | |
| Completed |
NCT00715091 -
Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis
|
Phase 4 | |
| Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
| Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
| Completed |
NCT00367211 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
|
Phase 3 | |
| Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 |